AG-13736 |
INLYTA |
AXITINIB |
AG-013736 |
AXITINIBUM |
AG 013736 |
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE |
INLYTA® |
AG013736 |
drugbank:06626 |
chemidplus:319460-85-0 |
chembl:CHEMBL1289926 |
rxcui:1242999 |
pubchem.compound:6450551 |
FDA Approval | Renal cell carcinoma |
Drug Class | Kinase Inhibitors |
FDA Approval | approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Pharmaceutical Developer | Pfizer |
Pharmaceutical Developer | Novartis |
Source Reported Drug Name(s) | Axitinib/AG013736/Inlyta |
Drug Class | Kinase Inhibitor |
Drug Categories | benzoates |
Drug Categories | acids, carbocyclic |
Drug Categories | amides |
Drug Categories | benzamides and benzamide derivatives |
Drug Categories | benzene derivatives |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | indazoles |
Drug Categories | kinase inhibitor |
Drug Categories | oatp1b1/slco1b1 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | receptor tyrosine kinase inhibitors |
Drug Categories | tyrosine kinase inhibitors |
Drug Categories | ugt1a1 substrates |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
n/a |
Alteration | VHL:. |
Drug family | [VEGFR inhibitor] |
combination therapy | [Sorafenib,Sunitinib,Bevacizumab,Axitinib] |
inhibitor (inhibitory) |
Trial Name | axitinib, AG-013736 |
Novel drug target | Established target |
Reported Cancer Type | Prostate |
inhibitor (inhibitory) |
Notes | |
Trial Name | axitinib, AG-013736 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Trial Name | axitinib, AG-013736 |
Novel drug target | Established target |
AXITINIB | DrugBank Drug Name |
319460-85-0 | CAS Number |
Inlyta | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Axitinib | PubChem Drug Name |
6450551 | PubChem Drug ID |
Inlyta | Drug Trade Name |
Drug Class | Kinase Inhibitor |
Source Reported Drug Name(s) | Axitinib/AG013736/Inlyta |
Pharmaceutical Developer | Novartis |
AG-013736 | Development Name |
AXITINIB | Generic Name |
INLYTA | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Renal cell carcinoma |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | approved |
AXITINIB | Primary Drug Name |
AXITINIB | Drug Generic Name |
INLYTA | Drug Trade Name |
AXITINIB | GuideToPharmacology Ligand Name |
CHEMBL1289926 | ChEMBL Drug ID |
D01ZRI | TTD Drug ID |